Evidence map›Paper›PMID 33583886›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.

Junsuke Tawara, Takanori Uehara, Seiichiro Sakao, Hidetoshi Igari, Toshibumi Taniguchi, Hajime Kasai, Shin Takayanagi, Misuzu Yahaba, Ryo Shimada, Masatomi Ikusaka

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Drug fever: a narrative review.Annals of clinical epidemiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Junsuke TawaraDepartment of General Medicine, Chiba University Hospital, Japan.
Takanori UeharaDepartment of General Medicine, Chiba University Hospital, Japan.
Seiichiro SakaoDepartment of Respiratory Medicine, Chiba University Hospital, Japan.
Hidetoshi IgariDepartment of Infectious Diseases, Chiba University Hospital, Japan.
Toshibumi TaniguchiDepartment of Infectious Diseases, Chiba University Hospital, Japan.
Hajime KasaiDepartment of Respiratory Medicine, Chiba University Hospital, Japan.
Shin TakayanagiDepartment of Infectious Diseases, Chiba University Hospital, Japan.
Misuzu YahabaDepartment of Infectious Diseases, Chiba University Hospital, Japan.
Ryo ShimadaDepartment of General Medicine, Chiba University Hospital, Japan.
Masatomi IkusakaDepartment of General Medicine, Chiba University Hospital, Japan.
Chiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 55-year-old Japanese man was hospitalized with the novel coronavirus disease 2019 (COVID-19). On the 14th day after the start of favipiravir administration, the patient developed a fever with a temperature of 38.1°C. His pulse rate also became elevated to 128 bpm, so relative bradycardia was not suspected. Since he was in good overall health and no concomitant symptoms and signs were apparent, we considered it to be drug fever due to favipiravir. After the completion of favipiravir treatment, the patient's temperature normalized within 24 hours. We herein report this case of drug fever caused by favipiravir.

Indexed as

COVID-19Pharmaceutical PreparationsAmidesAntiviral AgentsFeverHumansMaleMiddle AgedPyrazinesSARS-CoV-2AmidesAntiviral AgentsfavipiravirPharmaceutical PreparationsPyrazinesCOVID-19drug feverfavipiravirhyperuricemia

Identifiers

PMID33583886
PMCPMC8079902
OpenAlexW3132616841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.